A potential biomarker based on clinical-radiomics nomogram for predicting survival and adjuvant chemotherapy benefit in resected node-negative, early-stage lung adenocarcinoma.

J Thorac Dis · 2022 · PMC8828517 · PMID 35242363

Europe PMC DOI

hedged sentences

0.0530

closest p · 1.1× alpha

0.4580

boldest claim

The sentences

approximately significantP=0.053so close (0.05 < p ≤ 0.1)

The incremental benefit with the integration of radiomics signature was also significant in validation cohort (IDI =0.114; 95% CI: 0.026, 0.209; P=0.007) though NRI was not but approximately significant (0.395; 95% CI: −0.008, 0.613, P=0.053).

also in 60 other papers

did not reach statistical significanceP=0.458not close (p > 0.1)

In training cohort, the clinical-radiomics nomogram (C-index: 0.822; 95% CI: 0.769, 0.876) showed an improvement in predictive performance over clinical nomogram (C-index: 0.792; 95% CI: 0.733, 0.850) but it did not reach statistical significance (P=0.458).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.